05:14 PM EDT, 06/24/2024 (MT Newswires) -- Rigel Pharmaceuticals ( RIGL ) said late Monday it completed the transfer to Rigel of the new drug application for Gavreto to treat adults with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as well as adults and children 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.

Gavreto will be commercially available in the US starting June 27, the company said. Rigel reported its acquisition of the US commercial rights of the drug from Blueprint Medicines Corporation in February.

Price: 0.9788, Change: +0.02, Percent Change: +2.36